Induction of ovarian tumor-specific cd8+ cytotoxic t lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells

Obstetrics and Gynecology

Volumn 96, Issue 3, 2000, Pages 422-430

  Santin, Alessandro D ^a   Bellone, Stefania ^b   Ravaggi, Antonella ^c   Pecorelli, Sergio ^a   Cannon, Martin J ^b   Parham, Groesbeck P ^b  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ABDOMINAL HYSTERECTOMY; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; HUMAN; LYMPHOCYTE FUNCTION; MONONUCLEAR CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CYSTADENOCARCINOMA, PAPILLARY; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

FALLOPIA; HUMAN HERPESVIRUS 4;

EID: 0034734986     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006250-200009000-00019     Document Type: Article

References (29)

1. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT, eds. Clinical gynecologic oncology. St. Louis, Missouri: Mosby-Year Book, Inc., 1993:333-425.
2. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-9.
3. Nair SK, Boczkowski D, Snyder D, Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur ] Immunol 1997;27:589-97.
4. Zitvogel L, Majordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MX, et al. Therapy of murine tumors with tumor peptidepulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183: 87-97.
5. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70:706-15.
6. Storkus WJ, Zeh HJ, Salter RD, Lotze MT. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunotherapy 1993;14: 94-103.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
8. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
9. Santin AD, Hormonal PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pccorclli S, et al. Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7 pulsed autologous dendritic cells in patients with HPV16 and 18 positive cervical cancer. J Virol 1999;73:5402-10.
10. Romani N, Grüner S, Drang D, Kampgen E, Lenz A, Trockebacher D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Mcd 1994;160:83-93.
11. Santin AD, Rose GS, Hiserodt JC, Fruchauf J, Eck LM, Garcia RI, et al. Effects of cytokines combined with high dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Int J Cancer 1996;65:688-94.
12. Hopkins KA. Basic microlymphocytotoxicity test. In: ASHI laboratory manual. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics, 1990:195-201.
13. Nair S, Babu JS, Dunham RG, Kanda P, Burke RL, Rouse BT. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J Virol 1993;67:4062-9.
14. Nazaruk RA, Rochford R, Hobbs MV, Cannon MJ. Functional diversity of the CD8+ T cell response to Epstein-Barr virus (EBV): Implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 1998;91:3875-83.
15. Openshaw PJM, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K, et al. Heterogeneity of intracellular cytokine synthesis at the single cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995;182:1357-64.
16. Santin AD, loli GR, Hiserodt JC, Rose GS, Graf MR, Tocco LM, et al. Development and characterization of an IL-4 secreting human ovarian carcinoma cell line. Gynecol Oncol 1995;58: 230-9.
17. Santin AD, loli GR, Hiserodt JC, Manetta A, DiSaia PJ, Pecorelli S, et al. Development and characterization of an IL-2 transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. Am J Obstet Gynecol 1996; 174:633-40.
18. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-15.
19. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2: 52-8.
20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998;4:328-32.
21. Jerome KR, Domenech N, Finn OJ. Tumor specific CTL clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin cDNA. J Immunol 1993;151:1653-62.
22. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Association of Her-2/neu expression with sensitivity to tumor specific CTL in human ovarian cancer. J Immunol 1994;152: 2393-400.
23. Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ. Shared T cell epitopes in epithelial tumors. Cell Immunol 1995;164:279-86.
24. Fisk B, Anderson BVV, Gravitt KR, O'Brian CA, Kudelka AP, Murray JL, et al. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes. Cancer Res 1997;57:87-93.
25. Badger A, Oh S, Moolten F. Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody dependent cytotoxicity. Cancer Res 1981;41:1133-9.
26. Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, et al. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 1984;64:70S13.
27. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:147883.
28. Tsukui T, Hildesheim A, Schiffman MH, Lucci J III, Contois D, Lawler P, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology. Cancer Res 1996;56: 3967-74.
29. Romagnani S. Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992;98:279-85.